Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
GlobeNewswire
· Extended follow-up will include safety, kallikrein reduction and attack rate data, including number of patients who continue to..